Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure - Activity relationship (QSAR) with the Abraham descriptors

Journal of Pharmaceutical Sciences

Volumn 90, Issue 6, 2001, Pages 749-784

  Zhao, Yuan H ^a   Le, Joelle ^a   Abraham, Michael H ^a   Hersey, Anne ^b   Eddershaw, Peter J ^b   Luscombe, Chris N ^b   Boutina, Darko ^b   Beck, Gordon ^c   Sherborne, Brad ^c   Cooper, Ian ^c   Platts, James A ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ROCHE PRODUCTS LTD   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Intestinal absorption; QSAR; Solubility; Solvation equation

Indexed keywords

ACARBOSE; CISAPRIDE; DIAZEPAM; DIGOXIN; DISULFIRAM; FOSFOMYCIN; FUROSEMIDE; GALLOPAMIL; GLIBENCLAMIDE; IMIPRAMINE; INDOMETACIN; KANAMYCIN; LAMOTRIGINE; METFORMIN; METOPROLOL; MEXILETINE; NALOXONE; NAPROXEN; NEFAZODONE; PROPIVERINE; SALICYLIC ACID; SUDOXICAM; SULINDAC; SULTOPRIDE; TERAZOSIN; TOLBUTAMIDE; TOPIRAMATE; TORASEMIDE; UNINDEXED DRUG; VALPROIC ACID;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; EVALUATION; HUMAN; HUMAN TISSUE; INTESTINE ABSORPTION; MEMBRANE MODEL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; TECHNIQUE; URINARY EXCRETION;

EID: 0034992583     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.1031     Document Type: Article

References (271)

1. J. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases Part(I)
2. Clinical pharmacokinetics of new antiepileptic drugs
3. In vitro permeability across caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth
4. Use of a caco-2 cell culture model for the characterization of intestinal absorption of abtibiotics
5. MDCK (madin-darby canine kidney) cells: A tool for membrane permeability screening
6. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats
7. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption
8. Prediction of human intestinal absorption of drugs from molecular structure
9. Polar molecular surface properties predict and the intestinal absorption of drugs in humans
10. Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds
11. Prediction of intestinal drug absorption properties by three-dimensional solubility parameters
12. A general approach for the prediction of the intestinal absorption of drugs: Regression analysis using the physicochemical properties and drug-membrane electrostatic interaction
13. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
14. Correlation of drug absorption with molecular surface properties
15. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach
16. Pharmacokinetics of cisapride in healthy volunteers
17. Excretion and biotransformation of cisapride in dogs and humans after oral administration
18. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility
19. Pharmacokinetics and bioavailability of sodium valproate
20. Comparative bioavailability of aspirin from buffered, entericcoated and plain preparations
21. Pharmacokinetics of acetylsalicylic acid and salicylic acid after intravenous administration in man
22. Clinical pharmacokinetics of diazepam
23. Pharmacokinetics of oxicam nonsteroidal antiinflammatory agents
24. Effects of liver disease on pharmacokinetics - An update
25. Clinical pharmacokinetics of mexiletine
26. Clinical pharmacokinetics of nefazodone
27. Pharmacokinetics of naproxen in healthy volunteers and in patients with diabetic microangiopathy
28. Clinical pharmacokinetics of newer antiepileptic drugs - Lamotrigine, vigabatrin, gabapentin and oxcarbazepine
29. Pharmacokinetics of intravenous and oral tolmesoxide
30. Disposition and pharmacokinetics of disulfiram and calcium carbamide (calcium cyanamide)
31. Betaxolol - A new long-acting betal-selective adrenergic blocker
32. Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents
33. Disposition of naloxone-7, 8-3H in normal and narcotic-dependent man
34. Pharmacokinetics of terazosin
35. Clinical pharmacokinetics of sulindac - A dynamic old drug
36. Absorption, distribution and excretion of sultopride in man and several animal species
37. Topiramate - Clinical profile in epilepsy
38. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency
39. The pharmacokinetics and metabolism of propiverine in man
40. Pharmacokinetics of digoxin and main metabolite derivatives in healthy humans
41. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulfonate (mesna) in normal subjects
42. Pharmacokinetics/pharmacodynamics of furosemide in man: A review
43. Metformin kinetics in healthy-subjects and in patients with diabetes-mellitus
44. Clinical pharmacokinetics of metformin
45. The pharmacokinetics of rimiterol in man
46. Absorption, metabolism and elimination of strophanthus glycosides in man
47. Ascorbic-acid absorption in humans-A comparison among several dosage forms
48. Fosfomycin kinetics after intravenous and oral-administration to human volunteers
49. Fosfomycin: Absorption and excretion
50. Pharmacokinetic evaluation of fosfidomycin, a new phosphonic acid antibiotic
51. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir
52. Pharmacokinetics of acarbose. I. Absorption, concentration in plasma, metabolism and excretion after single administration of [c-14]acarbose to rats, dogs and man
53. Clinical pharmacokinetics of the antituberculosis drugs
54. Absorption of orally administered neomycin and kanamycin
55. Abnormal small intestinal permeability to sugars in patients with Crohn's disease of the terminal ileum and colon
56. Small intestinal permeability to mannitol, lactulose, and polyethylene glycol 400 in celiac disease
57. Lactulose CR-51 labelled ethylenediamine tetra-acetate, L-Rhamnose and polyethyleneglycol-500 as probe markers for assessment in vivo of human intestinal permeability
58. Species differences in the disposition and metabolism of camazepam
59. Pharmacokinetics of indomethacin in the elderly
60. Pharmacokinetic optimization of asthma treatment
61. Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines)
62. Clinical pharmacokinetics of imipramine and desipramine
63. Pharmacokinetics of fenclofenac following single and multiple doses
64. Influence of food and diet on gastrointestinal drug absorption: A review
65. Kinetics and biotransformation of lormetazepam
66. Clinical pharmacokinetics of diclofenc: Therapeutic insights and pitfalls
67. Metabolism and disposition of 14C-granisetron in rat, dog and man after intravenous and oral dosing
68. Absorption, metabolism, and excretion of oral testosterone in humans by mass fragmentography
69. Clinical pharmacokinetics of non-opiate abused drugs
70. The pharmacokinetics of ethinylestradiol in the presence and absence of gestodene and desogestrel
71. Ondansetron clinical pharmacokinetics
72. Verapamil: An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension
73. Absorption of steroid hormones from the human small intestine
74. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer
75. Pharmacokinetic optimisation of the treatment of neurocysticercosis
76. 3H cicaprost in healthy-volunteers
77. Metabolism of aminopyrine and derivatives in man-In-vivo study of monomorphic metabolic pathways
78. Desmethyldiazepam pharmacokinetics: Studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam
79. The metabolism of carfecillin in rat, dog and man
80. The metabolism of 4-14 C Prednisolone
81. The systemic availability of prednisolone after orally administered prednisone
82. Absorption potential-estimating the fraction absorbed for orally-administered compounds
83. Pharmacokinetics of propanolol
84. Blood level studies with viloxazine hydrochloride in man
85. Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment
86. Clinical pharmacokinetics and pharmacodynamics of warfarin - Understanding the dose-effect relationship
87. The gastrointestinal absorption of atropine in man
88. Clinical pharmacokinetics of vasodilators - Part I
89. Lack of effect of cholestyramine on the pharmacokinetics of clofibrate in man
90. Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man
91. Assay and pharmacokinetics of trimethoprim in man and animals
92. Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine
93. Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral-administration
94. Fate of [14 C]-bumetanide in man
95. Clinical pharmacokinetics of vasodilators - Part II
96. Clinical pharmacokinetics of fluconazole
97. Human pharmacokinetics of sotalol
98. Clinical pharmacokinetics of sotalol
99. Plasma concentrations of codeine and its metabolite, morphine, after single and repeated oral administration
100. Oral administration of codeine in the presence of ethanol - A pharmacokinetic study in man
101. Pharmacology of flumazenil
102. Stereoselective disposition of ibuprofen enantiomers in man
103. Pharmacokinetic studies of practolol, a beta adrenergic antagonist in man
104. Physiological disposition and metabolism of timolol in man and laboratory animals
105. Absorption of alprenolol in man from tablets with different rates of release
106. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (caco-2) cells
107. Clinical pharmacokinetics of ketoprofen and its enantiomers
108. 3-hydrocortisone in regional enteritis and ulcerative colitis, with a note on hydrocortisone production rates
109. The physiological disposition, and metabolic fate of hydrocortisone in man
110. Clinical pharmacokinetics of Keterolac Tromethamine
111. Clinical pharmacokinetics of meloxicam
112. Effect of dose on phenytoin absorption
113. Biochemical studies on chloramphenicol (chloromycetin). II. Tissue distribution and excretion studies
114. Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate
115. Evaluation of the elimination of 14C Felbamate in healthy men
116. Pharmacokinetics of opioids in liver disease
117. Clinical pharmacokinetics of nisoldipine coat-core
118. Bioavailability and pharmacokinetics of oxazepam
119. Single and multiple dose pharmacokinetics of tenidap sodium in healthy subjects
120. Felodipine kinetics in healthy men
121. Stereoselective pharmacokinetics of oral and intravenous mitrendipine in healthy male subjects
122. Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after iv and po administration
123. The pharmacokinetics of saccharin in man
124. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy patients
125. Clinical pharmacokinetics of lamivudine
126. Clinical pharmacokinetics of morphine
127. Disposition of captopril in normal subjects
128. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases
129. Zur pharmakokinetik von bromazepam beim menschen
130. Estimate of volume flow ratio of gastrointestinal (GI) fluids in humans using pharmacokinetic data
131. Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease
132. Disposition of SQ 32,756 (BV-araU) in healthy male subjects
133. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics
134. Absorption kinetics of oral and rectal flecainide in healthy subjects
135. Gastrointestinal absorption of quinidine from solutions and commercial tablets
136. Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration
137. Kinetics of oral ethambutol in the normal subject
138. Clinical pharmacokinetics of paracetamol
139. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma
140. Bioavailability of oral dexamethasone
141. Guanabenz - A review of its pharmacodynamic properties and therapeutic efficacy in hypertension
142. The clinical pharmacokinetics of famciclovir
143. Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure
144. Fenoterol: Review of its pharmacological properties and therapeutic efficacy in asthma
145. Comparative pharmacokinetic studies on fenoterol hydrobromide in rat, dog and man
146. The clinical importance of cardioselectivity and lipophilicity in beta blockers
147. Dose proportionality of nadolol pharmacokinetics after intravenous administration to healthy subjects
148. Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans
149. Metabolism and pharmacokinetics of orciprenaline in various animal species and man
150. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration of patients with human immunodeficiency virus
151. Pharmacokinetics of PN200-110 (isradipine), a new calcium-antagonist, after oral administration in man
152. Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate
153. Clinical pharmacokinetics of beta-agonists
154. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors
155. Pharmacokinetics of fluvaststatin after single and multiple doses in normal volunteers
156. The kinetics of propylthiouracil in Hyperthyroidism
157. The pharmacokinetics of propylthiouracil
158. Excretion and metabolism of recainam, a new antiarrhythmic drug, in laboratory-animals and humans
159. Pharmacokinetics of hydrochlorothiazide in man
160. Biotransformation of pirbuterol by the rat, dog, and human
161. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan
162. Disposition of sumatriptan in laboratory animals and humans
163. Sumatriptan clinical pharmacokinetics
164. Absorption, distribution and elimination of 14C-amiloride in normal human subjects
165. Human pharmacokinetics and tolerance of oral ganciclovir
166. Simultaneous assessment of intestinal permeability and lactose tolerance with orally administered raffinose, lactose and Larabinose
167. A pharmacokinetic comparison of cephalexin and cefadroxil using HPLC assay procedures
168. Pharmacokinetic factors in the modern drug treatment of tuberculosis
169. Pharmacokinetic profile of loracarbef
170. Intra- and inter-individual variation in pharmacokinetics of intravenously infused amoxycillin and ampicillin to elderly volunteers
171. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach
172. Pharmacokinetics of amoxicillin: Dose dependence after intravenous, oral and intramuscular administration
173. Dose-dependent absorption of amoxycillin and bacampicillin
174. Dose-dependent bioavailability of amoxycillin
175. Clinical pharmacology of new histamine H-1 receptor antagonists
176. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa
177. Human intravenous pharmacokinetics and absolute oral bioavailability of cefatrizine
178. Differential effect of type-i and type-ii diabetes-millitus on serum ampicillin levels
179. Pharmacokinetics and bioavailability of tranexamic acid
180. Kinetics of alpha-difluoromethylornithine - An irreversible inhibitor of ornithine decarboxylase
181. Methyldopa kinetics before and after ingestion of methyldopa for 8 weeks
182. Absorption of peptide and peptidomimetic drugs
183. Physicochemical higher throughput screening: Parallet artificial membrane permeation assay in the description of passive absorption precess
184. Absolute bioavailability, pharmacokinetics, renal and biliary clearance of distigmine after a single oral dose in comparison to i.v. administration of C-14-distigmine-bromide in healthy volunteers
185. Plasma and cerebrospinal fluid pharmacokinetics of 3′azido-3′-deoxythymidine - A novel pyrimidine analog with potential application for the treatment of patients with aids and related disease
186. Clinical pharmacokinetics of zidovudine - An update
187. Pharmacokinetics of the anti-inflammatory drug ximoprofen in healthy subjects and in disease states
188. Pharmacokinetics and concentration-effect relationships of intravenous and oral clonidine
189. Clinical pharmacokinetics of clonidine
190. Pharmacokinetics of clonidine
191. Pharmacokinetics of ceftizoxime with and without administration of probenecid
192. Physiological disposition of 2,2′-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine in humans
193. Clinical pharmacokinetics of Bretylium
194. The metabolism and biopharmaceutics of spironolactone in man
195. The clinical pharmacology of etoposide and teniposide
196. Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease
197. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in children
198. Effect of dose and food on the bioavailability of cefuroxime axetil Biopharm
199. Azithromycin clinical pharmacokinetics
200. Fosinopril - A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension
201. Pharmacokinetics of fosinopril in patients with various degrees of renal function
202. Disposition of pravastatin sodium, a tissue selective HMG-CoA reductase inhibitor, in healthy subjects
203. Cyclosporin clinical pharmacokinetics
204. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine
205. The effect of food and metoclopramide on the pharmacokinetics and side-effects of bromocriptine
206. The absorption of doxorubicin and mitomycin C in perioperative installation - An experimental and clinical study
207. Clinical pharmacokinetics of doxorubicin
208. Cefuroxime - A new cyclosporin antibiotic
209. Absorption of iothalamate after oral administration - A preliminary study in humans and interspecies differences
210. Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets
211. Benazepril - A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and congestive heart failure
212. The disposition of [14C]-labelled benazepril HC1 in normal adult volunteers after single and repeated oral dose
213. Lisinopril - A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure
214. Clinical pharmacokinetics of the newer ACE inhibitors - A review
215. Intestinal drug absorption during induced net water absorption in man - A mechanistic study using antipyrine, atenolol and enalaprilat
216. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors - A review
217. Enalapril maleate and a lysine analog (MK-521) - Disposition in man
218. Liposomal and lipid formulations of amphotericin-B - Clinical pharmacokinetics
219. Oral bioavailability of the monobactam aztreonam (sq 26,776) in healthy-subjects
220. Clinical pharmacokinetics of aztreonam
221. Clinical pharmacokinetics of mibefradil
222. Bioavailability of chlorothiazide from 50, 100, and 250 mg solution doses
223. Clinical pharmacokinetics of acyclovir
224. Norfloxacin - A review of its antibacterial activity, pharmacokinetic properties and therapeutic use
225. Review of the bioavailability and pharmacokinetics of oral norfloxacin
226. Clinical pharmacology of methotrexate
227. The clinical pharmacology of methotrexate
228. The metabolic fate of titrated methotrexate II. Absorption and excretion in man
229. Clinical pharmacokinetics of prazosin - 1985
230. Pharmacokinetic disposition of quinolines in human body fluids and tissues
231. The pharmacokinetics of olsalazine sodium in healthy volunteers after a single iv dose and after oral doses with and without food
232. Absolute oral bioavailability of ciprofloxacin
233. Comparative pharmacokinetics of antiviral nucleoside analogs
234. Pharmacokinetics of a single intravenous and oral dose of pafenolol - A beta 1-adrenoceptor antagonist with atypical absorption and disposition properties - In man
235. Azosemide kinetics and dynamics
236. Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers
237. Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: Absorption, disposition, and metabolism in man
238. Relative lipophilicities and structural pharmacological considerations of various angiotensinconverting enzyme (ACE) inhibitors
239. Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships: An overview
240. Absorption and decomposition of potassium - 35 Sphenoxymethyl penicillin
241. Pharmacokinetics of the penicillins in man
242. The physiological disposition of lovastatin
243. The absorption, excretion and metabolism of disodium [14C] cromoglycate in man
244. Clinical pharmacokinetic properties of the macrolide antibiotics - Effects of age and various pathophysiological states 1
245. Improved method for estimating water solubility from octanol water partition coefficient
246. Scales of hydrogen bonding: Their construction and application to physicochemical and biochemical processes
247. Hydrogen bonding Part 46. A review of the correlation and prediction of transport properties by an LFER method: Physicochemical properties, brain penetration and skin permeation
248. Hydrogen bonding 47. Characterization of the ethylene glycol - Heptane partition system; hydrogen bond acidity and basicity of peptides
249. Correlation and estimation of gas-chloroform and water-chloroform partition coefficients by a linear free energy relationship method
250. Solute-solvent interactions in normal-phase liquid chromatography, A linear free-energy relationships study
251. Solute-solvent interactions in micellar electrokinetic chromatography. Characterization of sodium dodecyl sulfate-Brij 35 micellar systems for quantitative structure-activity relationship modelling
252. The correlation and prediction of the solubility of compounds in water, An LFER approach using a modified solvation equation
253. The partition of volatile organic compounds from air and from water into plant cuticular matrix: An LFER analysis
254. Estimation of molecular linear free energy relation descriptors using a group contribution approach
255. Estimation of molecular linear free energy relationship descriptors by a group contribution approach 2. Prediction of partition coefficients
256. The absorption oral bioavailability of selected drugs
257. Pharmacokinetics of drugs in overdose
258. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings
259. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery
260. Role of P-glycoprotein and cytochrome P450. 3A in limiting oral absorption of peptides and peptidomimetics
261. Absorption prediction from physicochemical parameters
262. Pharmaco-kinetic changes during pregnancy and their clinical relevance
263. Computer aided design of experiments
264. Absorption of the beta-adrenergic-blocking agent, nadolol, by mice, rats, hamsters, rabbits, dogs, monkeys, and man: An unusual species difference